(Total Views: 737)
Posted On: 09/21/2020 4:26:37 PM
Post# of 156956
I don’t normally share from other sites, normally other way around but this seems fitting since it’s been very negative here lately.
“Dear Fellow Longs,
We should not trust Shorts more than, for example, Dr. Gero Hutter, one of CYDY Scientific Advisory Board and other World and National reknowned advisory members.
Dr. Hutter cured the first HIV patient [in the world] (The Berlin Patient, Timothy Ray Brown, an American) in 2008 (source: Wikipedia).
If Dr. Hutter does not have a very strong conviction in CYDY science, he is unlikely to jeopardize his own reputation by willingly consenting himself to be part of CYDY.
CYDY science is further bolstered by the recent testimonies of the 4 top doctors (Dr. Seethamraju, Dr. Yang, Dr. Agresti, Dr. Recknor). Do we choose to trust the Shorts more than these doctors?
Apart from their pursuit of monetary gains, in exchange, Shorts do not have any kind of "reputation" they put at stake on the table, for many of their scare tactics comments.
And, actually if Shorts don't trust CYDY, they don't need to buy CYDY, they can sell their shares, if any. It's as simple as that.
Shorts sticky involvement on this Board is to scare the weak hands investors and gain for their own benefits at the expense of Longs. They will say everything to keep the price low, because they cannot afford to cover the potential leap of CYDY shares price, when FDA/MHRA approves the drug for EUA (for S/C) in US or early access (for M/M) in UK.
Shorts relentlessly keep on posting negative ions many times in a day to wear you out and cause panic as you don't have time to verify. Be strong.
Do not trust the Shorts, but please do not be complacent, do your own due diligence to protect your own investments. Do spend time and read reliable scientific sources, to verify yourselves.
For a small biotech, it is not uncommon to have obstacles along the way in their business developments. I would be surprised if they don't have any. The Short are fondbof repeating old stories. But, as Longs we should focus on the science, its efficacy and safety aspects.
The Shorts are deceptive, they do not have sincere noble mission, they want you to be confused in their disguised messages and for you to sell your shares at cheap price. Do not fall into Shorts traps.
Leronlimab will be a blockbuster drug. In Leronlimab, we trust.
The EINDs have anecdotally proven efficacy and safety. The final CD-12 results by end Oct 2020 should be consistent and mirror the EINDs results.
Leronlimab will save lives in US and other parts of the world, hence gyrate the world economy again.
From a loyal true blue blood Long in CYDY.”
“Dear Fellow Longs,
We should not trust Shorts more than, for example, Dr. Gero Hutter, one of CYDY Scientific Advisory Board and other World and National reknowned advisory members.
Dr. Hutter cured the first HIV patient [in the world] (The Berlin Patient, Timothy Ray Brown, an American) in 2008 (source: Wikipedia).
If Dr. Hutter does not have a very strong conviction in CYDY science, he is unlikely to jeopardize his own reputation by willingly consenting himself to be part of CYDY.
CYDY science is further bolstered by the recent testimonies of the 4 top doctors (Dr. Seethamraju, Dr. Yang, Dr. Agresti, Dr. Recknor). Do we choose to trust the Shorts more than these doctors?
Apart from their pursuit of monetary gains, in exchange, Shorts do not have any kind of "reputation" they put at stake on the table, for many of their scare tactics comments.
And, actually if Shorts don't trust CYDY, they don't need to buy CYDY, they can sell their shares, if any. It's as simple as that.
Shorts sticky involvement on this Board is to scare the weak hands investors and gain for their own benefits at the expense of Longs. They will say everything to keep the price low, because they cannot afford to cover the potential leap of CYDY shares price, when FDA/MHRA approves the drug for EUA (for S/C) in US or early access (for M/M) in UK.
Shorts relentlessly keep on posting negative ions many times in a day to wear you out and cause panic as you don't have time to verify. Be strong.
Do not trust the Shorts, but please do not be complacent, do your own due diligence to protect your own investments. Do spend time and read reliable scientific sources, to verify yourselves.
For a small biotech, it is not uncommon to have obstacles along the way in their business developments. I would be surprised if they don't have any. The Short are fondbof repeating old stories. But, as Longs we should focus on the science, its efficacy and safety aspects.
The Shorts are deceptive, they do not have sincere noble mission, they want you to be confused in their disguised messages and for you to sell your shares at cheap price. Do not fall into Shorts traps.
Leronlimab will be a blockbuster drug. In Leronlimab, we trust.
The EINDs have anecdotally proven efficacy and safety. The final CD-12 results by end Oct 2020 should be consistent and mirror the EINDs results.
Leronlimab will save lives in US and other parts of the world, hence gyrate the world economy again.
From a loyal true blue blood Long in CYDY.”


Daniel Rizzo
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol
[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]
https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com
https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).
- Waiting…
whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…
Covid
That dosing/timeline mismatch wasn’t just a “mistake.” It sabotaged the trial.
• Day 0 & Day 7 dosing + 10-day half-life = patients had strong coverage through Day 14.
• But the FDA chose Day 28 as the evaluation point……. after drug levels had waned.
• That’s not science. That’s setting the bar where the drug was least likely to shine.
Whether by incompetence or intent, the design ensured leronlimab looked weaker than it actually was. That’s sabotage …..and the community knows it.
Federal Whistleblower
Case Numbers:
HHS & SEC Whistleblower: HL-1412396
DOJ Investigation Report/ Whistleblower ID: 20250705-0001
NIH Case Reference: CS1137565
DOD Case #16282
IC IG / 50 U.S.C. §3033
ARPA-H (Advanced Research Projects Agency for Health)
Founder & CEO of FireGate Bioscience
USPTO: Inventor of the HIV Cure Protocol

[/img]https://investorshangout.com/images/MYImages/1472647104_IMG_3103.png[/img]


https://investorshangout.com/images/MYImages/...G_2859.png
⸻
Public Links
FireGate Bioscience: https://www.firegatebioscience.com
NotYourDrug.com: https://www.notyourdrug.com

https://investorshangout.com/images/MYImages/..._3106.jpeg
https://investorshangout.com/images/MYImages/..._3107.jpeg
The underlying data is protected under federal law specifically 42 U.S.C. § 289b and its implementing regulation, 42 C.F.R. Part 93 through the Office of Research Integrity (askORI) within HHS, and coordinated with the Office of the Secretary / Office of Public Health and Science (OS/OPHS).



whistleblower_complaints@wyden.senate.gov belongs to Senator Ron Wyden, a senior Democratic U.S. Senator from Oregon.
We are watching YOU……
“This isn’t conspiracy, this is criminal suppression.” - Ohm
https://www.justice.gov/usao-sdny/pr/us-attor...r-programs
https://investorshangout.com/images/MYImages/..._3015.jpeg
???? What Leronlimab Does
• Target: CCR5 receptor (the same receptor people with the CCR5Δ32 mutation lack — like the “Berlin” and “London” patients who were cured after stem cell transplants).
• Effect: By binding CCR5, leronlimab blocks HIV entry into CD4 cells.
• Trial Data:
• In combination therapy trials, ~81% of patients achieved viral loads <50 copies/mL (suppression, not cure).
• As monotherapy, some patients maintained suppression for long stretches (months), but not universally.
⸻
???? Why It Might Be Seen as a “Cure”
• In theory, if you completely block CCR5 on all relevant cells, HIV can’t infect new cells.
• If existing infected reservoirs naturally decay without replenishment, the virus could eventually vanish.
• That’s exactly what happened in the Berlin/London patients — except through stem cell transplants with CCR5Δ32 donors, not a drug.
⸻
???? Why It Hasn’t Been Called a Cure (Yet)
1. HIV Reservoirs Persist
Leronlimab blocks new infection, but it doesn’t flush latent virus from cells. Once treatment stops, those reservoirs can reignite infection.
2. CCR5-Independent Pathways
Some HIV strains use CXCR4 or dual-tropism (CCR5 + CXCR4). Leronlimab won’t stop those.
3. Clinical Conservatism
Researchers avoid using the word “cure” unless patients remain off all therapy with no viral rebound for years. Leronlimab hasn’t shown that in trials.
⸻
???? So Could It Alone Cure HIV?
• In select cases (if someone’s virus is purely CCR5-tropic and their reservoirs naturally decay): maybe.
• But in the general population, it’s unlikely as a monotherapy cure. More realistic is using it as part of a cure combo approach…

Covid
That dosing/timeline mismatch wasn’t just a “mistake.” It sabotaged the trial.
• Day 0 & Day 7 dosing + 10-day half-life = patients had strong coverage through Day 14.
• But the FDA chose Day 28 as the evaluation point……. after drug levels had waned.
• That’s not science. That’s setting the bar where the drug was least likely to shine.
Whether by incompetence or intent, the design ensured leronlimab looked weaker than it actually was. That’s sabotage …..and the community knows it.
